Clinical trial
Endostar Continuous Intravenous Infusion Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC).
NCT03932266 is registered in ClinicalTrials.gov with Jiangsu Cancer Institute & Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Endostar Continuous Intravenous Infusion Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC).
- Lead sponsor
- Jiangsu Cancer Institute & Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 30, 2019
- Completion date
- September 30, 2023
- Enrollment
- 73 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.